Clinical TrialPTSDMDMAPlaceboCompleted

A Test of MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder

This Phase II, triple-blind, randomised, placebo-controlled study (n=23) evaluates MDMA-assisted therapy (125 mg + 62.5 mg) across two 8-hour sessions for chronic, treatment-resistant PTSD.

Target Enrollment
23 participants
Study Type
Phase II interventional
Design
Randomized, triple Blind

Detailed Description

Randomised, triple-blind, placebo-controlled trial comparing MDMA-assisted psychotherapy with psychotherapy plus inactive placebo in adults with chronic, treatment-resistant PTSD, including veterans.

Participants received two blinded 8-hour sessions (125 mg oral MDMA with a 62.5 mg supplemental dose, or matched placebo), with preparatory and integration therapy. Primary outcome: change in CAPS-IV two months post-treatment.

Study Protocol

Preparation

sessions

Dosing

2 sessions
480 min each

Integration

sessions

Therapeutic Protocol

support

Study Arms & Interventions

MDMA-AT

experimental

Two 8-hour MDMA-assisted psychotherapy sessions with a divided dose (125 mg + 62.5 mg).

Interventions

  • MDMA125 mg
    via Oraltwo sessions2 doses total

    Supplemental 62.5 mg 2–2.5 h after initial dose.

Placebo + therapy

inactive

Two 8-hour psychotherapy sessions with inactive placebo.

Interventions

  • Placebo
    via Oraltwo sessions2 doses total

Participants

Ages
1870
Sexes
Male & Female

Inclusion Criteria

  • Inclusion Criteria:
  • Have current PTSD (within the past 6 months) in response to crime victimization, including childhood sexual or physical abuse, or meet criteria for PTSD in response to combat;
  • Have a CAPS score showing moderate to severe PTSD symptoms;
  • They must either:
  • 1. Have had at least one unsuccessful attempt at treatment for PTSD with a SSRI and psychotherapy;
  • 2. Be a veteran with PTSD symptoms that have endured for no less than one year but no more than five years
  • Be at least 18 years old;
  • Must be generally healthy;
  • Willing to remain overnight at the study site;
  • Agree to have transportation home the morning after experimental sessions;
  • Are willing to be contacted via telephone for all necessary telephone contacts;
  • Must have a negative pregnancy test if able to bear children and agree to use an effective form of birth control;
  • Are proficient in reading English;

Exclusion Criteria

  • Exclusion Criteria:
  • Are pregnant or nursing, or are able to bear children and are not practicing an effective means of birth control;
  • Weigh less than 50 kg or more than 105 kg;
  • Are unable to give adequate informed consent;
  • Prior use of Ecstasy (illicit drug preparations purported to contain MDMA) more than 5 times or at any time within the previous 6 months;
  • Have a history of certain excluded medical disorders.

Study Details

  • Status
    Completed
  • Phase
    Phase II
  • Type
    interventional
  • Design
    Randomizedtriple Blind
  • Target Enrollment23 participants
  • Timeline
    Start: 2004-03-12
    End: 2010-06-21
  • Compounds
  • Topic

Locations

Offices of Michael Mithoefer MDMt. Pleasant, South Carolina, United States

Your Library